The explanatory memorandum explains why BlinkLab is holding a meeting: to approve past and future share issues, director and CEO participation in the raise, and incentive options. It also outlines how the $7.6M raised will fund FDA trials for autism/ADHD diagnostics and European regulatory approval.Directors and CEOs buying shares shows confidence so I’m stoked. The placement was priced at 0.30 and were quickly back up to 0.4s
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
47.5¢ |
Change
-0.005(1.04%) |
Mkt cap ! $41.44M | |||
| Open | High | Low | Value | Volume |
| 49.0¢ | 49.0¢ | 47.5¢ | $13.36K | 27.74K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20811 | 47.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.0¢ | 49623 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| BB1 (ASX) Chart |